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1. Introduction 
The role of residual renal function (RRF) in the health and quality of life of both pre-dialysis 
and dialysis patients is equally important and now well established (Termorshuizen, 
Korevaar et al, 2003). 
RRF plays an important role in maintaining fluid balance, phosphorus control, and removal 
of uremic toxins in dialysis patients. The importance of RRF in hemodialysis (HD) patients 
is less well appreciated and it is believed that RRF declined rapidly in HD patients 
(Morduchowicz, Winkler et al, 1994; Wang, Woo, et al, 2005). Decline of RRF also 
contributed significantly to anemia, inflammation, and malnutrition in end-stage renal 
disease (ESRD) patients (Wang, Sea et al, 2001; Pecoits-Filho, Heimburger et al, 2003; 
Pecoits-Filho, Heimburger et al, 2002; Wang, Wang et al, 2004). More importantly, RRF has 
also been shown to be a powerful predictor of mortality, especially in patients on peritoneal 
dialysis (PD) (Bargman, Thorpe et al, 2001; Brener, Thijssen et al, 2011; Maiorca, Brunori et 
al, 19951).  
Glomerular filtration rate (GFR) measured by isotope clearance is considered to be the 
standard measure of renal function. Other tests, such as serum creatinine, creatinine 
clearance, urea clearance, an average of the creatinine and urea clearances, and urine 
volume have been used to assess RRF in chronic kidney disease (Levey, 1990). Despite its 
limitations, urine volume, the simplest measure of RRF, has been correlated to GFR in 
studies and most authors defined loss of RRF as urine volume < 200 ml/24 hours (Moist, 
Port et al, 2000). Urine collections (24 hours for PD, interdialytic for HD) to measure urea 
and/or creatinine clearance usually done at beginning of chronic dialysis and every 1-3 
months in patients with RRF. 
In this chapter, we will review available data that have shown a positive impact of RRF on 
the survival and quality of life of dialysis patients, and outline the current strategies to 
preserve RRF in PD and HD patients.    
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2. The benefits of preserved RRF (Table 1) 
 
 Improving patients survival 
 Maintaining fluid balance 
 Blood pressure control 
 Decrease left ventricular hypertrophy 
 Anemia control 
 Phosphorus control 
 Potassium control 
 Uric acid control 
 Improving nutritional status 
 Decreasing inflammatory response 
Table 1. Benefits of preserved RRF 
2.1 RRF and patient survival (Table 2) 
In 1995, Maiorca et al noted an independent relationship between the presence of RRF and 
survival in dialysis patients (Maiorca, Brunori et al, 2011). In their multivariate survival 
analysis of 102 PD and HD dialysis patients, each 1-ml/min increase in GFR was associated 
with a 40% reduced risk of death in the entire cohort and a 50% reduced risk of death in PD 
patients. Multicenter prospective cohort Canada-USA (CANUSA) Study of 680 incident PD 
patients clearly demonstrated that the predictive power for mortality in PD patients was 
attributed to RRF and not to the dose of PD (Bargman, Thorpe et al, 2001). The impact of 
RRF on outcome has not been examined in large cohorts of HD patients, likely due to the 
more rapid rate of decrease in RRF and its smaller relative contribution to total small-
molecule clearance in HD compared with PD patients. In our retrospective study of 118 
incident HD patients survival time was significantly lower in patients without RRF (48 vs 55 
months) (Brener, Thijssen et al, 2011). Crude mortality was 19.4% in anuric patients and 
7.8% in patients with RRF, and cardiovascular disease was a leading cause of death for both 
groups. The presence of RRF was also associated with a strong trend toward fewer hospital 
days per patient-year. Shemin et al (Shemin, Bostom et al, 2001) reported that in the 
prospective observational study of 114 incident and prevalent HD patients, the presence of 
RRF was independently associated with a 65% decrease in risk of death, even after 
adjustment for duration of dialysis treatment, age, presence of diabetes, cardiovascular 
disease and serum albumin level.  Netherlands Cooperative Study on the Adequacy of 
Dialysis (NECOSAD) (Termorshuizen, Dekkeret al, 2004) has prospectively evaluated the 
contribution of treatment adequacy and RRF to patients survival after 3 and 6 months of 
treatment in a large incident HD population (740 patients). It showed the important 
 
 RRF is a powerful predictor of mortality 
 Each 1-ml/min increase in GFR was associated with a 40% reduced risk of death  
 Each 1-unit increase in renal Kt/V resulted in 66% decrease in relative risk of death 
 Independent relationship between the presence of RRF and survival in dialysis patients 
 Preservation of RRF is important in the survival of dialysis patients 
Table 2. RRF and dialysis patient survival  
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contribution of RRF to the overall survival of HD patients: each 1-unit increase in renal 
Kt/V resulted in 66% decrease in relative risk of death. Moreover, in patients with 
preserved RRF, increasing dialysis dose did not result in improved patient outcomes. The 
international prospective observational DOPPS study has also recently reported the diuretic 
use and presence of RRF was associated with a better survival in prevalent HD patients 
(Bragg-Gresham, Fissell et al, 2007). Diuretic use declined after the start of dialysis (9.2% in 
Europe versus 21.3% in the United States). Patients with RRF on diuretics had almost twice 
the chances of retaining RRF after 1 year with 7% lower all-cause and mortality and 14% 
lower cardiac-specific mortality compared to patients not receiving diuretics. All these and 
other observational studies suggest that preservation of RRF has an important role in the 
survival of both HD and PD patients.      
2.2 RRF, volume control and cardiac hypertrophy 
RRF has been found to be important in maintaining fluid balance of dialysis patients, 
especially in patients on PD. Suboptimal fluid removal in PD patients is associated with 
greater rates of all-cause hospitalization and mortality (Ates, Nergizoglu et al, 2001). In the 
CANUSA Study, urine volume was a strong independent predictor of survival. Every 250 
ml/imin urine output was associated with a 36% reduction in overall mortality ((Bargman, 
Thorpe et al, 2001). RRF may reduce or avoid the need for fluid restriction. Loss of RRF is 
independently associated with suboptimal blood pressure control, likely a result of chronic 
volume expansion (Ates, Nergizoglu et al, 2001; Konings, Kooman et al, 2003). The severity 
of left ventricular hypertrophy (LVH), a strong independent predictor of mortality in 
dialysis patients, inversely correlates with the presence of RRF Pecoits-Filho, Heimburger et 
al, 2002; Wang, Wang et al, 2004). In addition, loss of RRF is associated with more severe 
anemia, hypoalbuminemia, and higher arterial pressure (Pecoits-Filho, Heimburger et al, 
2003), all of which are important risk factors for cardiac hypertrophy in dialysis patients. 
Extracellular fluid (ECF) volume has been also reported to be associated with hypertension 
and left ventricular hypertrophy in HD patients (Fagugli, Pasini et al, 2003). 
2.3 RRF and metabolic control 
Middle molecule clearance is one of the most widely recognized benefits of RRF. Patients 
with significant RRF are shown to have lower ß2-mocroglobulin (ß2M) levels (McCarthy, 
Williams et al, 1994; Montenegro, Martinez et al, 1992; Amici G, Virga et al, 1993) and thus 
are less prone to dialysis-associated amyloidosis (Copley JB, Lindberg et al, 2001). Preserved 
RRF is also associated with lower blood levels of uric acid, potassium (Morduchowicz, 
Winkler et al, 1994), and aluminium (Altmann , Butter et al, 1987), and higher levels of 
hemoglobin (Pecoits-Filho, Heimburger et al, 2002), presumably due to increased levels of 
endogenous erythropoietin.  
Hyperphosphatemia is prevalent in dialysis patients (Yavuz, Ersoy et al, 2008; Wang, Woo 
et al, 2004) and has been linked to vascular calcification and increased cardiovascular 
mortality in both HD and PD patients (Block, Hulbert-Shearon et al, 1998; Wang AY, Lai et 
al, 2006).  RRF plays a major role in improving phosphate balance in both PD and HD 
patients ((Morduchowicz, Winkler et al, 1994). 
2.4 RRF and inflammation 
Inflammation is highly prevalent in dialysis patients (Arici M, Walls et al, 2001) and 
established to be a strong predictor of mortality in dialysis patients. Loss of RRF was 
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associated with an increased inflammatory response with elevated solute vascular cell 
adhesion molecules (VCAM-1) and C-reactive protein (CRP) levels in PD patients (Wang 
AY, Lam et al, 2005), possibly as a result of impaired renal elimination of proinflammatory 
cytokines and increased cytokine generation (Witko-Sarsat, Descamps-Latscha et al, 1997). 
Conversely, the presence of inflammation also accelerated the decline of RRF (Shin, Noh et 
al, 1999). 
2.5 RRF and nutritional status 
Malnutrition is a common serious problem in dialysis patients, may be result of multiple 
factors including impairments in protein and energy metabolism, hormonal imbalances and 
poor food intake because of anorexia (Ikizler, Hakim et al, 1996). Dialysis dose may affect 
nutritional status and low dialysis efficacy is associated with higher rates of morbidity and 
mortality (Gotch, Sargent, 1985; Bergstrom, Lindholm, 1993). RRF contributes significantly to 
the appetite and total caloric intake (Wang, Sea et al, 2001; Wang, Sea et al, 2005), and overall 
nutritional status assessed using subjective global assessment, handgrip strength, or lean 
body mass in both HD and PD patients. Nutritional status is closely related to inflammation. 
In our study (Brener, Thijssen et al, 2008) anuric HD patients were older with lower baseline 
serum albumin and showed a trend toward greater length of stay for all causes, and all 
cause mortality including infectious mortality. Analysis of albumin kinetics performed in 
HEMO Study showed that a decrease in serum albumin in adequately dialysed patients was 
mostly due to an increase in the level of inflammation, rather that a decrease in protein 
intake (Kaysen, Dubin et al, 2000). 
3. Preservation of RRF (Table 3) 
 
 PD modality 
 Avoidance of ECF volume depletion                        
 Avoidance of nephrotoxic insults (NSAIDs, radiocontrast agents, aminoglycosides) 
 Antihypertensive medications (ACE-inhibitors and calcium channel blockers) 
Table 3. Preservation of RRF 
3.1 Patient-related factors 
Decline of RRF is an unavoidable phenomenon caused by the degenerative and fibrosis 
process of chronic kidney disease (CKD). However, the rate of RRF loss is different among 
patients and may be affected by other factors such as patient-related factors, treatment 
modalities and practice patterns (Jansen, Hart et al, 2002). Patient-related factors include 
age, causal nephropathy and comorbid conditions. Decline of RRF has been shown to be age 
dependent (Hung, Young, 2003). Intercurrent events such as recurrent blood pressure drop 
during HD, cardiac events and sepsis may precipitate loss of RRF. Diabetics on PD have 
been shown to have a more rapid decline in RRF than nondiabetics (Singhal, Bhaskaran et 
al, 2000). Comorbid conditions, including congestive heart failure, poorly controlled 
hypertension, and coronary artery disease, also are associated with faster rates of RRF 
decrease (Shin, Noh et al, 1999). Patients with CKD secondary to glomerular disease lose 
RRF more rapidly than those with tubulointerstitial disease (Iest, Vanholder et al, 1989). In a 
large multicenter study, the majority of patients with adult polycystic kidney disease were 
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found to maintain a GFR greater than 2 ml/min for more than 4 years (Van Stone, 1995). 
Patients returning to dialysis therapy after kidney transplant failure have a more rapid 
decline in RRF than those initiating dialysis therapy with native kidney disease (Davies, 
2001). 
3.2 Impact of dialysis modality 
Observational studies showed the advantage of PD compared to HD in preserving RRF 
(Moist, Port et al, 2000; Rottembourg, Issad et al, 1983; Misra, Vonesh et al, 2001) but data 
from prospective randomized trials are lacking. PD is associated with better hemodynamic 
stability that may minimize ischemic renal insults and avoidance of the extracorporeal 
circulation of HD that promotes systemic inflammation, oxidative stress, and subsequent 
kidney injury (Rottembourg, Issad et al, 1983). Treatment with ultrapure dialysate and 
biocompatible membranes has been shown to slow the loss of RRF in incident HD patients 
(Schiffl , Lang et al, 2002). It has been suggested use of PD as an initial dialysis modality in 
patients with RRF to maximize RRF conservation and thus survival for patients on dialysis.  
3.3 Avoidance of ECF volume depletion 
Observational data from NECOSAD Study suggest that episodes of volume depletion were 
an independent risk factor for the loss of RRF (Termorshuizen, Korevaar et al, 2003).1 In a 
study by Gunal et al (Gunal AI, Duman et al, 2001) strict volume control in 47 PD patients 
led to 6% decrease in left ventricular hypertrophy and 28% decrease in mean urine volume 
in the 19 patients with RRF. Subclinical hypovolemia, even in presence of normal blood 
pressure, can lead to a decrease in RRF as a result of overzealous ECF volume depletion. 
Diuretics have been shown to increase urine volume and sodium removal, but do not affect 
the solute clearance (Moist, Port et al, 2000; van Olden, Guchelaar et al, 2003), and can be 
used, where appropriate, to provide better control of volume balance. As mentioned above, 
the extended use of loop diuretics may help to prolong diuresis and preserve RRF. 
Correction of fluid volume excess by combining dietary salt restriction and gentle 
ultrafiltration is a simple and effective approach to control hypertension and to reverse LVH 
(Konings, Kooman et al, 2003). 
3.4 Avoidance of nephrotoxic insults 
Avoiding the use of radiocontrast agents or nephrotoxic drugs such as non-steroidal anti-
inflammatory drugs or aminoglycosides is an important approach in protecting RRF. 
Aminoglycoside nephrotoxicity can be decreased by once-daily dosing, avoidance of 
concomitant nephrotoxins, monitoring of drug levels, and choice of the least nephrotoxic 
aminoglycoside used (Baker, Senior et al, 2003). Recent trials that used either adequate 
hydration, low-osmolar radiocontrast agents (Dittrich, Puttinger  et al, 2006) as well as 
prophylactic acetylcysteine (Tepel, van der Giet et al, 2000) did not show long-term decline 
after contrast exposure despite a temporary decline in GFR immediately after contrast 
exposure.  
3.5 Antihypertensive medications 
ACE-inhibitors and calcium channel blockers were associated with preservation of RRF in 
both PD and HD patients (Tepel, van der Giet et al, 2000). In a prospective study by Li PK et 
al (Li PK, Chow et al, 2003), PD patients treated with ramipril had a slower rate of RRF loss 
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compared to the control group. Investigation of the role of combination therapy with ACE 
inhibitors and ARBs and direct aldosterone blockade on RRF represent promising future 
strategies in slowing the rate of RRF decline in dialysis patients. 
4. Conclusion 
RRF contributes to the clearance of both small and medium-sized solutes. It serves 
important metabolic and hemodynamic functions, and plays a crucial role in maintaining 
the cardiovascular health, nutritional status, and well-being of dialysis patients. RRF has 
also been shown to have a significant impact on the survival of dialysis patients, especially 
in PD dialysis. Health care providers need to realize that RRF is a very valuable asset to 
dialysis patients. Efforts to preserve RRF should continue even after patients are started on 
dialysis treatment, irrespective of the modality used 
5. References 
Altmann P, Butter KC, Plowman D, Chaput de Saintonge DM, Cunningham J & Marsh FP. 
Residual renal function in hemodialysis patients may protect against 
hyperaluminemia. Kidney Int, Vol.32, no.5, (November 1987), pp. 710-713 
Amici G, Virga G, Da Rin G, Grandesso S, Vianello A, Gatti P & Bocci C. Serum beta-2- 
microglobulin level and residual renal function in peritoneal dialysis. Nephron, 
Vol.65, No.3, (March 1993), pp. 469-471 
Arici M & Walls J. End-stage renal disease, atherosclerosis, and cardiovascular mortality: is 
C-reactive protein the missing link? Kidney Int, Vol.59, No.2, (February 2001), pp. 
407-414 
Ates K, Nergizoglu G, Keven K, Sen A, Kutlay S, Ertürk S, Duman N, Karatan O & Ertuğ 
AE. Effect of fluid and sodium removal on mortality in peritoneal dialysis patients. 
Kidney Int,Vol.60, No.2, (August 2001), pp.767-776 
Baker RJ, Senior H, Clemenger M & Brown EA. Empirical aminoglycosides for peritonitis do 
not affect residual renal function. Am J Kidney Dis; Vol.41, No.3, (March 2003), pp. 
670-675 
Bargman JM, Thorpe KE & Churchill DN. Relative contribution of residual renal function 
and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA 
study. J Am Soc Nephrol; Vol.12, No.10, (October 2001), pp. 2158-2162.  
Bergstrom J& Lindholm B. Nutrition and adequacy of dialysis. How do hemodialysis and 
CAPD compare? Kidney Int Suppl, Vol.43, (February 1993), pp. S39-50 
Block GA, Hulbert-Shearon TE, Levin NW & Port FK. Association of serum phosphorus and 
calcium * phosphate product wit mortality risk in chronic hemodialysis patients: A 
national study. Am J Kidney Dis; Vol.31, No.4, (April 1998), pp. 607-617 
Bragg-Gresham JL, fissell RB, Mason NA, Baille GR, Gillespie BW, Wizemann V, Cruz JM, 
Akiba T, Kurokawa K, Ramirez S, Young EW. Diuretic use, residual renal function, 
and mortality among hemodialysis patients in the Dialysis Outcomes and Practice 
Pattern Study (DOPPS). Am J Kidney Dis; Vol.49(3), (March 2007), pp. 426-431  
www.intechopen.com
 
Residual Renal Function in Hemodialysis Patients 
 
261 
Brener ZZ Thijssen S, Kotanko P, Kuhlmann MK, Winchester JF & Levin NW. The impact of 
residual renal function on infectious outcomes in incident hemodialysis patients. J 
Am Soc Nephrol; Vol.18 (2008), pp. 291 
Brener ZZ, Thijssen S, Kotanko P, Kuhlmann MK, Bergman M, Winchester JF, Levin NW. 
The impact of residual renal function on hospitalization and mortality in incident 
hemodialysis patients. Blood Purif, Vol.31, No. 4, (January 2011), pp. 243-251 
Copley JB & Lindberg JS. Nontransplant therapy for dialysis-related amyloidosis. Semin 
Dial, Vol.14, (2001), pp. 94-98 
Davies SJ. Peritoneal dialysis in the patient with a failing renal allograft. Perit Dial Int, Vol. 
21, (2001), pp. S280-S284  
Dittrich E, Puttinger H, Schillinger M, Lang I, Stefenelli T, Hörl WH & Vychytil A. Effect of 
radio contrast media on residual renal function in peritoneal dialysis patients– A 
prospective study. 
Fagugli, RM, Pasini P, Quintaliani G, Pasticci F, Ciao G, Cicconi B, Ricciardi D, Santirosi PV, 
Buoncristiani E, Timio F, Valente F & Buoncristiani U. Association between 
extracellular water, left ventricular mass and hypertension in haemodialysis 
patients. Nephrol Dial Transplant, Vol.18, No.11, (November 2003), pp. 2332-2338 
Gotch F & Sargent J. A mechanistic analysis of the National Cooperative Dialysis study 
(NCDS). Kidney Int, Vol.28, No.2, (February 1985), pp. 526-534 
Gunal AI, Duman S, Ozkahya M, Töz H, Asçi G, Akçiçek F & Basçi A. Strict volume control 
normalizes hypertension in peritoneal dialysis patients. Am J Kidney Dis, Vol.37, 
No.3, (March 2001), pp. 588-593 
Hung AM, Young BS, Chertow GM. The decline in residual renal function is slow and age 
dependent. Hemodial Int, Vol. 7, (2003), pp. 17 
Iest CG, Vanholder RC, Ringoir SM. Loss of residual renal function in patients on regular 
haemodialysis. Int J Artif Organs, vol. 12, (1989), pp. 159-164 
Ikizler TA & Hakim RM. Nutrition in end-stage renal disease. Kidney Int, Vol.50, No.2, 
(August 1996), pp. 343-57 
Jansen MA, Hart AA, Korevaar JC, Dekker FW, Boeschoten EW, Krediet RT; NECOSAD 
Study Group. Predictors of the rate of decline of residual renal function in incident 
dialysis patients. Kidney Int, Vol. 62, pp. 1046-1053 
Kaysen GA, Dubin JA, Muller HG, Rosales LM & Levin NW. The acute-phase response 
varies with time and predicts serum albumin levels in hemodialysis patients. The 
HEMO Study Group. Kidney Int, Vol.8, No.1, (July 2005), pp. 346-352 
Konings CJ, Kooman JP, Schonck M, Struijk DG, Gladziwa U, Hoorntje SJ, van der Wall 
Bake AW, van der Sande FM & Leunissen KM. Fluid status in CAPD patients is 
related to peritoneal transport and residual renal function: Evidence from a 
longitudinal study. Nephrol Dial Transplant,Vol.18, no.4, (April 2003), pp. 797-803 
Levey AJ. Measurement of renal function in chronic renal disease. Kidney Int 1990; Vol. 38, 
No.1, (July 1990), pp. 167-184 
Li PK, Chow KM, Wong TY, Leung CB & Szeto CC. Effects of an angiotensine-converting 
enzyme inhibitor on residual renal function in patients receiving peritoneal 
dialysis. A randomized, controlled study. Ann Intern Med, Vol.139, No.2, (July 
2003), pp. 105-112 
www.intechopen.com
 
Progress in Hemodialysis – From Emergent Biotechnology to Clinical Practice 
 
262 
Maiorca R, Brunori G, Zubani R, Cancarini GC, Manili L, Camerini C, Movilli E, Pola A, 
d'Avolio G & Gelatti U. Predictive value of dialysis adequacy and nutritional 
indices for mortality and morbidity in CAPD and HD patients. A longitudinal 
study. Nephrol Dial Transplant, Vol.10, No.12, (December 1995), pp. 2295-2305 
McCarthy JT, Williams AW & Johnson WJ. Serum beta 2-microglobulin concentration in 
dialysis patients: importance of intrinsic renal function. J Lab Clin Med, Vol.123, 
No.4, (April 1994), pp. 495-505 
Misra M, Vonesh E, Van Stone JC, Moore HL, Prowant B & Nolph KD. Effect of cause and 
time of dropout on the residual GFR: a comparative analysis of the decline of GFR 
on dialysis. Kidney Int; Vol.59, No.2, (February 2001), pp. 754-763 
Moist LM, Port FK, Orzol SM, Young EW, Ostbye T, Wolfe RA, Hulbert-Shearon T, Jones 
CA & Bloembergen WE.Predictors of loss of residual renal function among new 
dialysis patients. J Am Soc Nephrol, Vol.11, No.3, (March 2000), pp.556-564   
Montenegro J, Martinez I, Sarachet & Gonzelez R. Beta 2 microglobulin in CAPD. Adv Perit 
Dial, Vol.8, (1992), pp. 369-372 
Morduchowicz G, Winkler J, Zabludowski JR & Boner J. (1994). Effects of residual renal 
function in hemodialysis patients. Int Urol Nephrol, Vol.26, No.1, (1994), pp. 125-131.  
Pecoits-Filho R, Heimburger M, Woo J, Law MC, Chow KM, Li PK, Lui SF & Sanderson JE. 
A novel association between residual renal function and left ventricular 
hypertrophy in peritoneal dialysis patients. Kidney Int, Vol.62, No.2, (August 2002), 
pp. 639-647.  
Pecoits-Filho R, Heimburger O, Barany P, Bárány P, Suliman M, Fehrman-Ekholm I, 
Lindholm B   & Stenvinkel P. Associations between circulating inflammatory 
markers and residual renal function in CRF patients. Am J Kidney Di,s Vol.41, No.6, 
(June 2003), pp. 1212-1208.  
Rottembourg J, Issad B, Gallego JL, Degoulet P, Aime F, Gueffaf B & Legrain M. Evolution 
of residual renal function in patients undergoing maintenance haemodialysis or 
continuous ambulatory peritoneal dialysis. Proc Eur Dial Transplant Assoc., Vol.19, 
(1983), pp. 397-403 
Schiffl H, Lang SM & Fischer R. Ultrapure dialysis fluid slows loss of residual renal function 
in new dialysis patients. Nephrol Dial Transplant 2002; Vol.17, No.10, (October 2002), 
pp. 1814-1818 
Shemin D, Bostom AG, Laliberty P & Dworkin LD. Residual renal function and mortality 
risk in hemodialysis patients. Am J Kidney Dis, Vol.38, No.1, (July 2001), pp. 85-90.  
Shin SK, Noh H, Kang SW, Seo BJ, Lee IH, Song HY, Choi KH, Ha SK, Lee HY & Han DS. 
Risk factors influencing the decline of residual renal function in continuous 
ambulatory peritoneal dialysis patients. Perit Dial Int, Vol.19, No.2, (March 1999), 
pp. 138-142  
Singhal MK, Bhaskaran S, Vidgen E, Bargman JM, Vas SI, Oreopoulos DG. Rate of decline of 
residual renal function in patients on continuous peritoneal dialysis and factors 
affecting it. Perit Dial Int, Vol.20, (2000), pp. 429-438 
Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D & Zidek W. Prevention of 
radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. 
N Engl J Med, Vol.343, no.3, (July 2000), pp. 180-184 
www.intechopen.com
 
Residual Renal Function in Hemodialysis Patients 
 
263 
Termorshuizen F, Dekker FW, van Manen JG, Korevaar JC, Boeschoten EW & Krediet RT. 
NECOSAD Study Group: Relative contribution of residual renal function and 
different measures of adequacy to survival in hemodialysis patients: an analysis of 
the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD)-2. J 
Am Soc Nephrol, Vol.15, No.4, (April 2004), pp. 1061-1070.  
Termorshuizen F, Korevaar JC, Dekker FW, van Manen JG, Boeschoten EW & Krediet RT. 
(2003). NECOSAD Study Group: The relative importance of residual renal function 
compared with peritoneal clearance for patient survival and quality of life: an 
analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis 
(NECOSAD )-2. Am J Kidney Dis, Vol.41, No.6, (June 2003), pp. 1293-1302.  
van Olden RW, Guchelaar HJ, Struijk DG, Krediet RT & Arisz L. Acute effects of high-dose 
furosemide on residual renal function in CAPD patients. Perit Dial Int 2003; Vol.23, 
No.4, (July 2003), pp. 339-347 
Van Stone JC. The effect of dialysis membrane and etio9logy of kidney disease on the 
preservation of residual renal function in chronic hemodialysis patients. ASAIO J, 
Vol. 41, (1995), pp. M713-M716 
Wang AY & Lai KN. The importance of residual renal function in dialysis patients. Kidney 
Int, Vol.69, No.10, (May 2006), pp.1726-1732 
Wang AY, Lam CW, Wang M, Woo J, Chan IH, Lui SF, Sanderson JE & Li PK. Circulating 
soluble vascular cell adhesion molecule 1: relationships with residual renal 
function, cardiac hypertrophy, and outcome of peritoneal dialysis patients. Am J 
Kidney Dis,Vol.45, No.4, pp. 715-729  
Wang AY, Sea MM, Ho ZS, Lui SF, Li PK & Woo J. Evaluation of handgrip strength as a 
nutritional marker and prognostic indicator in peritoneal dialysis patients. Am J 
Clin Nutr. Vol.81, No.1, (January 2005), pp. 79-86 
Wang AY, Sea MM, Ip R, Law MC, Chow KM, Lui SF, Li PK & Woo J. Independent effects of 
residual renal function and dialysis adequacy on actual dietary protein, calorie, and 
other nutrient intake in patients on continuous ambulatory peritoneal dialysis. J Am 
Soc Nephrol, Vol.12, No.11, (Nov 2001), pp. 2450-2457.  
Wang AY, Wang M, Woo J, Lam CW, Lui SF, Li PK & Sanderson JE. Inflammation, residual 
renal function, and cardiac hypertrophy are interrelated and combine adversely to 
enhance mortality and cardiovascular death risk of peritoneal dialysis patients. J 
Am Soc Nephrol, Vol.15, No.8, (August 2004), pp. 2186-2194.  
Wang AY, Woo J, Sea MM, Lui SF & Li PK. Hyperphosphatemia in Chinese peritoneal 
dialysis patients with and without residual renal function: What are the 
implications? Am J Kidney Dis, Vol.43, No.4, (April 2004), pp. 712-720 
Wang AY, Woo J, Wang M, See MM, Sanderson LE, Lui SF & Li PK. Important 
differentiation of factors that predict outcome in peritoneal dialysis patients with 
different degrees of residual renal function. Nephrol Dial Transplant, Vol.20, No.2, 
(Feb 2005), pp. 396-403.  
Witko-Sarsat V & Descamps-Latscha B. Advanced oxidation protein products: Novel 
uraemic toxins and proinflammatory mediators in chronic renal failure? Nephrol 
Dial Transplant, Vol.12, no.7, (July 1997), pp. 1310-1312 
www.intechopen.com
 
Progress in Hemodialysis – From Emergent Biotechnology to Clinical Practice 
 
264 
Yavuz A, Ersoy FF, Passadakis PS, Tam P, Evaggelos DM, Katopodis KP, Ozener C, Akçiçek 
F, Camsari T, Ateş K, Ataman R, Vlachojannis GJ, Dombros NA, Utaş C, Akpolat T, 
Bozfakioğlu S, Wu G, Karayaylali I, Arinsoy T, Stathakis CP, Yavuz M, Tsakiris DJ, 
Dimitriades AC, Yilmaz ME, Gültekin M, Süleymanlar G & Oreopoulos DG. 
Phosphorus control in peritoneal dialysis patients. Kidney Int Suppl, Vol.108, (2008), 
pp. S152-158 
www.intechopen.com
Progress in Hemodialysis - From Emergent Biotechnology to
Clinical Practice
Edited by Prof. Angelo Carpi
ISBN 978-953-307-377-4
Hard cover, 444 pages
Publisher InTech
Published online 07, November, 2011
Published in print edition November, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
Hemodialysis (HD) represents the first successful long-term substitutive therapy with an artificial organ for
severe failure of a vital organ. Because HD was started many decades ago, a book on HD may not appear to
be up-to-date. Indeed, HD covers many basic and clinical aspects and this book reflects the rapid expansion of
new and controversial aspects either in the biotechnological or in the clinical field. This book revises new
technologies and therapeutic options to improve dialysis treatment of uremic patients. This book consists of
three parts: modeling, methods and technique, prognosis and complications.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Zachary Z. Brener, Stephan Thijssen, Peter Kotanko, James F. Winchester and Michael Bergman (2011).
Residual Renal Function in Hemodialysis Patients, Progress in Hemodialysis - From Emergent Biotechnology
to Clinical Practice, Prof. Angelo Carpi (Ed.), ISBN: 978-953-307-377-4, InTech, Available from:
http://www.intechopen.com/books/progress-in-hemodialysis-from-emergent-biotechnology-to-clinical-
practice/residual-renal-function-in-hemodialysis-patients
© 2011 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
